RenovoRx Reports Record Q1 Revenue, Extends Cash Runway, and Nears Phase III Trial Enrollment Completion
RNXT sits 22% above its 52-week low of $0.701.
Summary
RenovoRx announced strong first-quarter 2026 financial results, driven by record revenue growth and expanding commercial adoption of its RenovoCath device, while also extending its cash runway into late 2027 and nearing full enrollment in its pivotal Phase III clinical trial.
Key Events · Earnings and Guidance · RNXT
-
Record Q1 Revenue Growth
Reported Q1 2026 revenue of $563,000, a 136% increase quarter-over-quarter, representing over 50% of the total revenue generated in full year 2025.
-
Extended Cash Runway
Ended the quarter with $12.4 million in cash, which is believed to be sufficient to fund operations into at least the second half of 2027.
-
Commercial Expansion
Active commercial cancer center customers expanded to 16, with a robust pipeline of 32 additional centers and a target of 36 active centers by year-end 2026.
-
Phase III Trial Nearing Enrollment Completion
The TIGeR-PaC clinical trial is 93% enrolled (106 of 114 patients), with full enrollment expected by June 2026.
Analysis · RNXT · Life Sciences
This filing highlights significant operational and financial progress for RenovoRx. The company reported a substantial 136% quarter-over-quarter revenue increase, demonstrating strong commercial momentum for its RenovoCath device and expanding customer base. Critically, the company has extended its cash runway into the second half of 2027, providing crucial financial stability for its ongoing operations and clinical development. Additionally, the Phase III TIGeR-PaC trial is on track for full enrollment by June 2026, marking a key milestone in its long-term value creation strategy.
At the time of this filing, RNXT was trading at $0.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.5M. The 52-week trading range was $0.70 to $1.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.